Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1971 1
1979 1
1983 1
1985 1
1986 2
1988 3
1989 2
1990 3
1991 6
1992 12
1993 5
1994 9
1995 6
1996 18
1997 11
1998 13
1999 12
2000 22
2001 9
2002 20
2003 17
2004 24
2005 13
2006 11
2007 21
2008 11
2009 18
2010 16
2011 31
2012 35
2013 34
2014 37
2015 40
2016 50
2017 45
2018 97
2019 118
2020 147
2021 142
2022 109
2023 83
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,133 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. Suker M, et al. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160474 Free PMC article. Review.
BACKGROUND: 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. ...The proportion of patients who underwent surgical resection for locally advanced pancreatic cancer ranged from 0% to 43%. The proportion of p …
BACKGROUND: 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. ...The proportion …
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan HS, Tait IS, Prachalias A, Ross P, Valle JW, O'Reilly DA, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim KL, Cunningham D, Armstrong T, Archer C, Roberts K, Ma YT, Springfeld C, Tjaden C, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Ghaneh P, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521500 Free article. Clinical Trial.
METHODS: ESPAC5 (formerly known as ESPAC-5f) was a multicentre, open label, randomised controlled trial done in 16 pancreatic centres in two countries (UK and Germany). Eligible patients were aged 18 years or older, with a WHO performance status of 0 or 1, biopsy proven …
METHODS: ESPAC5 (formerly known as ESPAC-5f) was a multicentre, open label, randomised controlled trial done in 16 pancreatic centres …
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D, Klint L, Dueland S, Lassen K; Nordic Pancreatic Cancer Trial-1 study group. Labori KJ, et al. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38237621 Clinical Trial.
BACKGROUND: In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. ...Future trials on treatment sequenci …
BACKGROUND: In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, an …
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. Eshmuminov D, et al. Ann Surg Oncol. 2023 Jul;30(7):4417-4428. doi: 10.1245/s10434-023-13353-2. Epub 2023 Apr 5. Ann Surg Oncol. 2023. PMID: 37020094 Free PMC article. Review.
BACKGROUND: Pancreatic cancer often presents as locally advanced (LAPC) or borderline resectable (BRPC). ...
BACKGROUND: Pancreatic cancer often presents as locally advanced (LAPC) or borderline resectable (BRPC). ...
A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer.
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, Okusaka T, Furuse J. Ozaka M, et al. Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023. doi: 10.1007/s00280-018-3577-9. Epub 2018 Apr 9. Cancer Chemother Pharmacol. 2018. PMID: 29633005 Clinical Trial.
BACKGROUND: We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for chemotherapy-naive patients with metastatic pancreatic cancer. METHODS: Patients with untreated metastatic pancreatic cancer (MPC) received modified FOLFIRINOX (intra …
BACKGROUND: We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for chemotherapy-naive patients with metastatic pancrea …
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Sugimoto M, et al. BMC Cancer. 2021 Dec 9;21(1):1319. doi: 10.1186/s12885-021-09069-9. BMC Cancer. 2021. PMID: 34886831 Free PMC article.
BACKGROUND: The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). ...
BACKGROUND: The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluoroura …
Bias and Pancreatic Cancer Reporting.
Hochster HS, Alexander HR. Hochster HS, et al. J Natl Cancer Inst. 2022 May 9;114(5):641-642. doi: 10.1093/jnci/djac020. J Natl Cancer Inst. 2022. PMID: 35157049 Free PMC article. No abstract available.
Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G, Innocenti F, Minami H. Milano G, et al. Cancer Sci. 2022 Jul;113(7):2224-2231. doi: 10.1111/cas.15377. Epub 2022 May 26. Cancer Sci. 2022. PMID: 35445479 Free PMC article. Review.
However, irinotecan has not been successfully introduced as a second-line treatment for pancreatic cancer and few randomized clinical studies have evaluated its added value. ...Liposomal irinotecan is currently under investigation in other malignancies including bil …
However, irinotecan has not been successfully introduced as a second-line treatment for pancreatic cancer and few randomized c …
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z. BMC Cancer. 2021. PMID: 33757440 Free PMC article.
METHODS: This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is de …
METHODS: This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and bo …
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, Ohno E, Ishikawa T, Maeda O, Ogawa H, Kodera Y, Nagino M, Ebata T. Yamaguchi J, et al. Ann Surg. 2022 Jun 1;275(6):1043-1049. doi: 10.1097/SLA.0000000000005430. Epub 2022 Mar 3. Ann Surg. 2022. PMID: 35258510 Clinical Trial.
OBJECTIVE: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified. SUMMARY OF BACKGROUND DATA: Although the development o …
OBJECTIVE: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using ne …
1,133 results